Figure 4
![Figure 4. TP53 mutations do not influence clinical endpoints in F-refractory CLL treated with alemtuzumab. (A) OS of patients with F-refractory CLL stratified by TP53 and 17p status (n = 99). The median survival for patients with and without TP53 mutation was 13.6 months versus 21.3 months, respectively. The groups with the 17p deletion, TP53 mutation without 17p−, and all other patients also showed similar OS (18.6 [17p−], 19.9 [TP53 mutation, no 17p−], and 19.1 months [neither TP53 mutation nor 17p−]). (B) The TTTF was very similar for patients with or without the TP53 mutation (median time to treatment failure, 5.8 vs 4.6 months) and irrespective of 17p status (median TTTF, 5.0 [17p−], 11.1 [no 17p−/TP53 mutation], and 5.3 months [neither]).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/114/13/10.1182_blood-2009-05-224071/4/zh89990942460004.jpeg?Expires=1722718818&Signature=I0i44EVX9FfpOMn~MT~87ZapSE8PLBi7-E-oCqkqion-Hs-B1lWmMCSmaV1W4dX-5SL6m39PRkQRPV2ix~AitWRwB2LdxGOUOcYaLkqLkOLBIC-CR7tTp3mQXGY6zK8u~Xdyh27CkwSSTfzoFHrdIh2NGfdXRgP3cgMZ3DBRG9PQT2iFsB9eZSkaxqg82WlThzyftPDFP5gHrgaQ~uZ3pYOs5UD7gsP3Fia71L2XwauNmO5EjuMQ2faDg-2KEDZvvg4V4KSUnPg8wP5Ev2kmeTvX~WV6t-5wZroeAgL3genv5GT4t48DAFu2KDKqTyzBJ9bBEiUDAE8pTTYFq91pgQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
TP53 mutations do not influence clinical endpoints in F-refractory CLL treated with alemtuzumab. (A) OS of patients with F-refractory CLL stratified by TP53 and 17p status (n = 99). The median survival for patients with and without TP53 mutation was 13.6 months versus 21.3 months, respectively. The groups with the 17p deletion, TP53 mutation without 17p−, and all other patients also showed similar OS (18.6 [17p−], 19.9 [TP53 mutation, no 17p−], and 19.1 months [neither TP53 mutation nor 17p−]). (B) The TTTF was very similar for patients with or without the TP53 mutation (median time to treatment failure, 5.8 vs 4.6 months) and irrespective of 17p status (median TTTF, 5.0 [17p−], 11.1 [no 17p−/TP53 mutation], and 5.3 months [neither]).
